Studies open for Enrollment
ABCSG 53 / TAXIS / SAKK 23/16
A multicenter randomized phase III trial to compare tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer
ABCSG 55N /AMBHER
Description of patients with HER2 positive breast cancer undergoing neoadjuvant treatment and development of a dynamic composite risk score to predict the risk of distant recurrence
ABCSG 60 / CAMBRIA-1
A phase III, open-label, randomized study to assess the efficacy and safety of extended therapy with camizestrant versus standard endocrine therapy in patients with ER+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed at least 2 years of standard adjuvant endocrine-based therapy without disease recurrence.
ABCSG 61 / TEODOR
Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness
A prospective, randomized, controlled, open-label multicenter phase II study investigating neoadjuvant endocrine therapy versus chemotherapy in HR-positive, HER2-negative, ctDNA-negative and endocrine responsive early and locally advanced breast cancer
ABCSG 62 / CAMBRIA-2
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.
ABCSG 63 / ERIKA
Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer
An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer
ABCSG 65 / DEFINITIVE
Diagnostic HER2DX-guided treatment For patIeNts wIth early-stage HER2-posiTIVE breast cancer
An international, multicenter, prospective, two-arm, randomized, open-label Phase III study designed to demonstrate that personalized treatment decisions in HER2-positive early-stage breast cancer using the HER2DX® diagnostic test improve quality of life without compromising outcomes and survival rates.
ABCSG 67N / CAROLEEN
A non-interventional study for ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence to evaluate real-world effectiveness, safety profile, patient compliance and quality of life
Share on